282 related articles for article (PubMed ID: 18204982)
1. Regulation of prolactin receptor levels and activity in breast cancer.
Swaminathan G; Varghese B; Fuchs SY
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):81-91. PubMed ID: 18204982
[TBL] [Abstract][Full Text] [Related]
2. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
Kavarthapu R; Dufau ML
Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
[TBL] [Abstract][Full Text] [Related]
3. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
4. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
[TBL] [Abstract][Full Text] [Related]
5. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
6. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
7. Impaired turnover of prolactin receptor contributes to transformation of human breast cells.
Plotnikov A; Varghese B; Tran TH; Liu C; Rui H; Fuchs SY
Cancer Res; 2009 Apr; 69(7):3165-72. PubMed ID: 19276348
[TBL] [Abstract][Full Text] [Related]
8. The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.
Fiorillo AA; Medler TR; Feeney YB; Wetz SM; Tommerdahl KL; Clevenger CV
Am J Pathol; 2013 Jan; 182(1):217-33. PubMed ID: 23159947
[TBL] [Abstract][Full Text] [Related]
9. Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies.
Ginsburg E; Alexander S; Lieber S; Tarplin S; Jenkins L; Pang L; Heger CD; Goldsmith P; Vonderhaar BK
BMC Cancer; 2010 Dec; 10():678. PubMed ID: 21144038
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain.
Kline JB; Rycyzyn MA; Clevenger CV
Mol Endocrinol; 2002 Oct; 16(10):2310-22. PubMed ID: 12351696
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of the intermediate isoform of the human prolactin receptor.
Kline JB; Roehrs H; Clevenger CV
J Biol Chem; 1999 Dec; 274(50):35461-8. PubMed ID: 10585417
[TBL] [Abstract][Full Text] [Related]
12. New mechanisms for PRLr action in breast cancer.
Clevenger CV; Gadd SL; Zheng J
Trends Endocrinol Metab; 2009 Jul; 20(5):223-9. PubMed ID: 19535262
[TBL] [Abstract][Full Text] [Related]
13. Characterization of multiple first exons in murine prolactin receptor gene and the effect of prolactin on their expression in the choroid plexus.
Tabata H; Kobayashi M; Ikeda JH; Nakao N; Saito TR; Tanaka M
J Mol Endocrinol; 2012 Apr; 48(2):169-76. PubMed ID: 22294444
[TBL] [Abstract][Full Text] [Related]
14. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer.
Hachim IY; Hachim MY; Lopez VM; Lebrun JJ; Ali S
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):238-45. PubMed ID: 26317306
[TBL] [Abstract][Full Text] [Related]
15. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.
Standing D; Dandawate P; Anant S
Front Endocrinol (Lausanne); 2022; 13():1112987. PubMed ID: 36714582
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of prolactin receptor in breast cancer cells.
Li Y; Clevenger CV; Minkovsky N; Kumar KG; Raghunath PN; Tomaszewski JE; Spiegelman VS; Fuchs SY
Oncogene; 2006 Mar; 25(13):1896-902. PubMed ID: 16278670
[TBL] [Abstract][Full Text] [Related]
17. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
Bogorad RL; Courtillot C; Mestayer C; Bernichtein S; Harutyunyan L; Jomain JB; Bachelot A; Kuttenn F; Kelly PA; Goffin V; Touraine P;
Proc Natl Acad Sci U S A; 2008 Sep; 105(38):14533-8. PubMed ID: 18779591
[TBL] [Abstract][Full Text] [Related]
18. Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer.
Nitze LM; Galsgaard ED; Din N; Lund VL; Rasmussen BB; Berchtold MW; Christensen L; Panina S
Breast Cancer Res Treat; 2013 Nov; 142(1):31-44. PubMed ID: 24146212
[TBL] [Abstract][Full Text] [Related]
19. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
Gutzman JH; Miller KK; Schuler LA
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
[TBL] [Abstract][Full Text] [Related]
20. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
